Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorThird Affiliated Hospital, Sun Yat-Sen University
About this trial
This study aims to investigate the efficacy and safety of artificial liver support system treatment for immune checkpoint inhibitors related liver failure in patients with hepatocellular carcinoma.
Eligibility criteria
Qualifiers
Age from 18 to 65 years old;
Clinical diagnosis of chronic hepatitis b virus infection (positive hepatitis b surface antigen or positive hepatitis b virus DNA > 0.5 year);
Clinical diagnosis of hepatocellular carcinoma and receive immune checkpoint inhibitors treatment. The last treatment of immune checkpoint inhibitors is less than three months from inclusion;
The level of hepatitis b virus DNA < 2000 IU/mL；
Disqualifiers
Other active liver diseases;
Other malignancy;
Pregnancy or lactation;
Human immunodeficiency virus infection or congenital immune deficiency diseases;
Trial design
Treatments tested in this trial
- DPMAS+LPE
- PE
- Comprehensive internal medical treatment
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov